FAETH THERAPEUTICS INC

FAETH THERAPEUTICS sees Khosla Ventures stake and insider buys signal confidence, yet its early‑stage oncology platform remains highly speculative with a negative P/E and limited market cap. This article breaks down the implications, market sentimen…

Faeth Therapeutics CFO’s bulk buying shows insider confidence in a promising CAR‑T pipeline and strong upside potential—investors should watch this trend.